恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点

21世纪经济报道
13 hours ago

3月25日,恒瑞医药(600276.SH,01276.HK)发布2025年年度报告。财报显示,全年实现营业收入316.29亿元,同比增长13.02%;归属于上市公司股东的净利润77.11亿元,同比增长21.69%;归属于上市公司股东的扣除非经常性损益的净利润74.13亿元,同比增长20.00%。  这一增速显著超出行业平均水平。但更值得关注的并非简单的财务增长数字,而是隐藏在报表背后的结构性变化—...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10